Recommendations for Appropriate Activated Partial Thromboplastin Time Reagent Selection and Utilization

被引:37
作者
Fritsma, George A. [1 ,2 ,3 ]
Dembitzer, Francine R. [4 ]
Randhawa, Ankush [5 ]
Marques, Marisa B. [1 ,2 ]
Van Cott, Elizabeth M. [6 ]
Adcock-Funk, Dorothy [7 ]
Peerschke, Ellinor I. [4 ]
机构
[1] Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Div Lab Med, Sch Med, Birmingham, AL 35294 USA
[3] Your Interact Hemostasis Resource, Fritsma Factor, Trussville, AL USA
[4] Mt Sinai Sch Med, Dept Pathol, New York, NY USA
[5] Precis BioLog, Dartmouth, NS, Canada
[6] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[7] Esoterix, Englewood, CO USA
关键词
aPTT; Lupus anticoagulant; Activated partial thromboplastin time; Reagent; Routine coagulation; HEPARIN;
D O I
10.1309/AJCP3J1ZKYBFQXJM
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The activated partial thromboplastin time (aPTT) is widely used as a screening coagulation test and for monitoring unfractionated heparin therapy. Various commercial reagents are available, with different performance characteristics, particularly responsiveness to the lupus anticoagulant (LA). Because aPTT reagent selection significantly affects the interpretation of results, we reviewed College of American Pathologists proficiency testing data involving approximately 4,000 coagulation laboratories, and conducted a survey of coagulation laboratories (n = 93) using The Fritsma Factor hemostasis Web site to determine the basis for aPTT reagent selection. The data demonstrate that for routine aPTT testing, most laboratories use reagents with high/moderate responsiveness to LA. Significant misunderstanding was apparent regarding the use of appropriate aPTT reagent for routine testing and LA identification. We recommend aPTT reagents with low LA responsiveness to screen for coagulation factor deficiencies and heparin monitoring, and suggest continued education of laboratory professionals and reagent manufacturers about appropriate aPTT reagent use.
引用
收藏
页码:904 / 908
页数:5
相关论文
共 12 条
[1]  
[Anonymous], COLL AM PATH PROF TE
[2]  
[Anonymous], 2012, HEMATOLOGY CLIN PRIN
[3]  
[Anonymous], SEMIN THROMB HEMOST
[4]  
[Anonymous], 1983, LAB EVALUATION COAGU
[5]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[6]   NEWER APPROACHES TO THE STUDY OF HEMOPHILIA AND HEMOPHILIOID STATES [J].
BRINKHOUS, KM ;
LANGDELL, RD ;
PENICK, GD ;
GRAHAM, JB ;
WAGNER, RH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1954, 154 (06) :481-486
[7]   Lupus Anticoagulant Testing Performance and Practices by North American Clinical Laboratories [J].
Dembitzer, Francine R. ;
Kraemer, Marlies R. Ledford ;
Meijer, Piet ;
Peerschke, Ellinor I. B. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (05) :764-773
[8]   Update of the guidelines for lupus anticoagulant detection [J].
Pengo, V. ;
Tripodi, A. ;
Reber, G. ;
Rand, J. H. ;
Ortel, T. L. ;
Galli, M. ;
de Groot, P. G. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (10) :1737-1740
[9]   Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines [J].
Swadzba, J. ;
Iwaniec, T. ;
Pulka, M. ;
De Laat, B. ;
De Groot, P. G. ;
Musial, J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (09) :1776-1783
[10]  
TRIPLETT DA, 1978, AM J CLIN PATHOL, V70, P556